FibroGen obtains FDA approval for FG-3165 Phase 1 trial, partners with Regeneron for clinical trials.
FibroGen receives US FDA approval for FG-3165 Phase 1 trial on a galectin-9 targeted monoclonal antibody for solid tumor treatment. The company also announces a clinical trial supply agreement with Regeneron to evaluate FG-3165 and FG-3175 with Regeneron's anti-PD-1 therapy LIBTAYO in patients with solid tumors. FibroGen shares increased by 22.76% after hours at $1.23.
June 03, 2024
4 Articles